reports
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipate...
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., J...
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to use the net proceeds from the offerin...
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares o...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Admin...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RID...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 20...
Centene Corp: 1 director
A director at Centene Corp sold 66,007 shares at 39.020USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and P...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 ...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPE...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Trans...
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therap...
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking Presentation on Sunday to Showcase Results of Cellular Reprogramming Gene Therapy Treatment in Pig Model of Ischemic Heart Failure Tenaya Management to Host Webcast Conference Call on Monday, November 10, 2025,...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XENE XENON PHARMACEUTICALS INC
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
LTRX LANTRONIX INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LAKE LAKELAND INDUSTRIES INC.
CEVA CEVA INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALB ALBEMARLE CORPORATION
EFR ENERGY FUELS
RELL RICHARDSON ELECTRONICS LTD.
NTLA INTELLIA THERAPEUTICS INC.
UAMY UNITED STATES ANTIMONY CORP.
BOMN BOSTON OMAHA
ICL ICL GROUP LTD.
LWLG LIGHTWAVE LOGIC
IMTX IMMATICS N V (A)
ARRY ARRAY TECHNOLOGIES
IMVT IMMUNOVANT
RLAY RELAY THERAPEUTICS
FLUX FLUX POWER HOLDINGS
GLUE MONTE ROSA THERAPEUTICS INC
ASTS AST SPACEMOBILE INC
TRDA ENTRADA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
APLD APPLIED BLOCKCHAIN INC
IE IVANHOE ELECTRIC INC
NUVL NUVALENT INC
COHR COHERENT CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
GPCR STRUCTURE THERAPEUTICS
OCS OCULIS HOLDING AG
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
METBV FORTREA HOLDINGS INC.
FTREV SAGIMET BIOSCIENCES INC
SGMT BYRNA TECHNOLOGIES INC
BYRN ENGENE HOLDINGS INC
ENGN SPYRE THERAPEUTICS INC.
SYRE NEUROGENE INC
NGNE RAMACO RESOURCES INC.
METC TOYO CO LTD
TOYO SERVE ROBOTICS INC
SERV UPSTREAM BIO INC
UPB CIDARA THERAPEUTICS INC.
CDTX AMERICAN BATTERY TECHNOLOGY COMPANY
ABAT TVARDI THERAPEUTICS INC
TVRD USA RARE EARTH INC
USAR HYCROFT MINING HOLDING CORPORATION
HYMC CATALYST PERINI STRATEGIC INCOM ORD
CSIOX CHARGEPOINT HOLDINGS INC.
CHPT KULR TECHNOLOGY GROUP INC.
KULR GRAFTECH INTERNATIONAL LTD.
EAF GLOBALSTAR INC.
GSAT INHIBRX BIOSCIENCES INC.
INBX KON TUM CONSTRUCTION MATERIALS ORD
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicine...
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual...
Tenaya Therapeutics to Participate in Upcoming October Investor Confer...
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below: Cell & Gene Meeting on the Mesa Date: Monday, October 6Time: 8:00 AM MT – 9:00 A...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rul...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 202,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exerci...
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual G...
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET. The live...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TNDM TANDEM DIABETES CARE INC
RYAM RAYONIER ADVANCED MATERIALS INC
OPK OPKO HEALTH INC.
NEO NEOGENOMICS INC.
MTDR MATADOR RESOURCES COMPANY
KURA KURA ONCOLOGY INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
ICUI ICU MEDICAL INC.
EMN EASTMAN CHEMICAL COMPANY
EIG EMPLOYERS HOLDINGS INC.
D DOMINION ENERGY INC
COTY COTY INC. CLASS A
CNC CENTENE CORPORATION
CHD CHURCH & DWIGHT CO. INC.
ARW ARROW ELECTRONICS INC.
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
AROW ARROW FINANCIAL CORP.
KODK EASTMAN KODAK CO
AAOI APPLIED OPTOELECTRONICS INC.
ADC AGREE REALTY CORPORATION
HTLD HEARTLAND EXPRESS INC.
BSM BLACK STONE MINERALS LP
VVV VALVOLINE INC.
GBLI GLOBAL INDEMNITY PLC
FTV FORTIVE CORP.
SMRT SMARTSPACE SOFTWARE
CCEL CRYO-CELL INTERNATIONAL
SONO SONOS
ESTA ESTABLISHMENT LABS HOLDINGS
WU THE WESTERN UNION COMPANY
TROX TRONOX HOLDINGS PLC
LUMN LUMEN TECHNOLOGIES INC.
VTRS VIATRIS INC
ENVX ENOVIX CORP
PTLO PORTILLOS INC
EBC EASTERN BANKSHARES INC
MSDL MORGAN STANLEY DIRECT LENDING
BKKT BAKKT HOLDINGS INC.
FIP FTAI INFRASTRUCTURE INC
MRAI MARPAI
MDRR INC.
BOOM MEDALIST DIVERSIFIED REIT INC.
EFOI DYNAMIC MATERIALS CORPORATION
STSS ENERGY FOCUS INC.
SHARPS TECHNOLOGY INC.
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural Histor...
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No Approved Therapeutics Genotypic Status Identified as a Significant Predictor of Risk and Left Ventricular Mass Index May Serve as a Surrogate Marker for Poor Long-Term Outcomes SOUTH SAN FRANCIS...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
- Dave Nicoski
- Ross LaDuke
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
SBH SALLY BEAUTY HOLDINGS INC.
RGEN REPLIGEN CORPORATION
PSX PHILLIPS 66
PNFP PINNACLE FINANCIAL PARTNERS INC.
LLY ELI LILLY AND COMPANY
HRTX HERON THERAPEUTICS INC
CROX CROCS INC.
CNC CENTENE CORPORATION
CHD CHURCH & DWIGHT CO. INC.
CBZ CBIZ INC.
AKAM AKAMAI TECHNOLOGIES INC.
ASA ASA
WY WEYERHAEUSER COMPANY
KODK EASTMAN KODAK CO
MXCT MAXCYTE INC
AAOI APPLIED OPTOELECTRONICS INC.
ADC AGREE REALTY CORPORATION
PETS PETMED EXPRESS INC.
SGMS SCIENTIFIC GAMES CORPORATION
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
CYRX CRYOPORT INC.
ICHR ICHOR HOLDINGS LTD.
UA UNDER ARMOUR
SMRT INC.
BHC SMARTSPACE SOFTWARE
SONO BAUSCH HEALTH COMPANIES INC.
ESTA SONOS
TROX ESTABLISHMENT LABS HOLDINGS
AMPY TRONOX HOLDINGS PLC
PINE AMPLIFY ENERGY
FOUR ALPINE INCOME PROPERTY TRUST
ASAN SHIFT4 PAYMENTS
DLHC INC.
LUMN ASANA
GRNT DALEIGH HOLDINGS CORP
PRCT LUMEN TECHNOLOGIES INC.
ENVX GRANIT SKOPKE
PTLO PROCEPT BIOROBOTICS CORP
BRCC ENOVIX CORP
BRBR PORTILLOS INC
MSDL BRC INC
INSG BELLRING BRANDS INC
SUNS MORGAN STANLEY DIRECT LENDING
INSEEGO CORP.
SUNRISE REALTY TRUST
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.